Keyphrases
Base Pairing
50%
Biological Cells
50%
Biological Error
50%
Biological Samples
50%
Biotechnology
100%
Blood-based
50%
Blood-based Diagnostics
50%
Bst Polymerase
50%
Cancer Marker
50%
CBM2
100%
Cell-free DNA (cfDNA)
100%
Cell-to-cell
50%
Chamber Array
50%
Circulating Markers
100%
Circulating Tumor Cells
50%
Clinical Decisions
50%
Clinical Utility
50%
Collaborative Projects
50%
Complementary DNA (cDNA)
50%
Current Imaging
50%
DNA Methylation (DNAm)
50%
DNA mutation
50%
Early Cancer
50%
Early Detection
50%
Endonuclease
50%
Enzymatic Reaction
100%
Exosomes
100%
Gene Copy number Variation
50%
High Purity
50%
Highly Accurate
50%
Imaging Technology
50%
Infectious Diseases
50%
Infiltration
50%
Innovative Features
50%
Innovative Technologies
50%
Ligase Detection Reaction
100%
Limited Access
50%
Linear Extension
50%
Low Abundance
50%
Methylation Status
100%
MiRNA Expression
50%
MiRNA Target
50%
Molecular Diagnostics
100%
Molecular Profiling
50%
Multiscale Systems
100%
Peripheral Blood
50%
Personalized Treatment
50%
Processing Strategies
50%
Promoter Methylation
50%
Reaction Products
50%
Resource Center
100%
RNA Sequencing (RNA-seq)
50%
Single-dimension
50%
Solid Phase
100%
Solid Support
50%
Spill
50%
Status Sequence
50%
Stroke Disease
50%
Terminal Deoxynucleotidyl Transferase
50%
Treatment Decisions
50%
Treatment Efficacy
50%
Unmet Medical Need
50%
Viral Load
50%
Whole Blood
50%
Whole Blood Sample
50%
Biochemistry, Genetics and Molecular Biology
Base Pairing
33%
Copy-Number Variation
33%
DNA Mutation
33%
Endonuclease
33%
Flight
33%
Gene Dosage
33%
Genomic Fragment
33%
Ligase
66%
Messenger RNA
33%
Methylation
100%
MicroRNA
33%
Polymerase
33%
Promoter Region
33%
RNA
33%
RNA Sequence
33%
Solid
66%
Terminal Deoxynucleotidyl Transferase
33%
Tumor Marker
33%
Virus Load
33%
Pharmacology, Toxicology and Pharmaceutical Science
Base
33%
Cerebrovascular Accident
33%
Combination Therapy
33%
Complementary DNA
33%
Diseases
100%
DNA Nucleotidylexotransferase
33%
Early Cancer
33%
Endonuclease
33%
Ligase
66%
Messenger RNA
33%
microRNA
33%
Neoplasm
33%
Recurrent Disease
33%
Tumor Marker
33%